GeoVax Labs, Inc. (GOVX) Stock Score, Valuation & Financial Research
GeoVax Labs, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 27/100.
Quick answer for GOVX
GeoVax Labs, Inc. currently has a Wall Street Score of 27/100. The stored market price is $0.45. Its financial score is 50/100. Its valuation score is 0/100. The latest WSS change is -1.4 points. These figures are a research snapshot, not a buy or sell recommendation.
What GeoVax Labs, Inc. does
GeoVax Labs, Inc. is a biotechnology company in the clinical development phase, focused on creating innovative human vaccines and immunotherapies. The firm targets both infectious diseases and various cancer types, utilizing its proprietary modified vaccinia ankara (MVA) virus-like particle (VLP) vaccine platform. Its product pipeline includes several prophylactic vaccines aimed at preventing illnesses such as COVID-19, human immunodeficiency virus (HIV), Zika virus, malaria, and a range of hemorrhagic fevers like Ebola, Sudan, Marburg, and Lassa. Additionally, GeoVax is developing therapeutic vaccines designed to treat existing conditions, specifically HIV, chronic Hepatitis B infections, and solid tumor cancers. To support its research and development efforts, GeoVax Labs, Inc. has forged partnerships with notable organizations. These collaborators include the National Institute of All
GOVX financial snapshot
- Wall Street Score:
- 27/100
- Current price:
- $0.45
- Market capitalization:
- $3.3M
- Revenue:
- $0
- Net income:
- $-20.4M
- Free cash flow:
- $-21.5M
- Cash:
- $3.1M
- Total debt:
- $323K
- EPS:
- -2.77
- Financial score:
- 50/100
- Valuation score:
- 0/100
- Revenue score:
- 0/100
What stands out
- Reported year-over-year revenue growth is -1.0%.
- Free cash flow is $-21.5M, showing cash burn in the current stored period.
- The balance sheet shows $3.1M of cash versus $323K of total debt, leaving more cash than debt.
- The latest Wall Street Score change is -1.4 points: GOVX decreased 1.4 points because Asset declined by 14.1 points.
- The current research record carries a share basis reconciled warning, which should be reviewed alongside the score.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 50/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-08-14.
How to research GOVX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.